Revenue segments as reported by the company.

Grant revenue

Clinical trial revenue

Contract revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

General and administrative

Research and development

Selling and marketing

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Longeveron

Longeveron, Inc. is a clinical stage biotechnology company. It engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffers on October 9, 2014 and is headquartered in Miami, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Longeveron reports promising Q1 results, secures funding for growth

Longeveron's Q1 2024 earnings call highlighted positive Phase I results for HLHS and cost management efforts. The company secured funding for further development and welcomed new board members. Challenges include regulatory hurdles and market competition, but opportunities lie in expanding therapeutic applications and revenue growth potential.

Longeveron reports positive Q2 results, eyes contract services expansion

Longeveron's Q2 2024 earnings call highlighted strong performance in trials and financials, with a focus on HLHS program advancement and contract services expansion. The company faces challenges in addressing analyst inquiries and maximizing its contract services business potential, but has opportunities for revenue growth and leveraging positive trial outcomes.

Longeveron reports robust revenue growth and progresses towards FDA approval

Longeveron's Q3 2024 performance reflects strong revenue growth and advancements in regulatory pathways for their product candidate, Lomecel-B, across multiple therapeutic areas.
The company's focus on cellular therapies aligns with a lucrative market potential in the U.S., but funding needs for accelerated activities and competitive challenges pose considerations for future strategies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.

Longeveron Inc. (NASDAQ:LGVN ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Representatives Dr. Chris Min - Interim Chief Executive Officer, Chief Medical Officer Dr. Joshua Hare - Co-Founder, Chief Science Officer, Chairman James Clavijo - Chief Financial Officer Elsie Yau - Stern Investor Relations Conference Call Participants Michael Okunewitch - Maxim Group Operator Good morning or good afternoon, and welcome to the Longeveron Inc., 2022 Third Quarter Earnings Call. My name is Ajay and I will be your operator today.

Longeveron Inc. (LGVN) Q3 2022 Earnings Call Transcript

-- Achieved key clinical and regulatory milestones across clinical pipeline, including the completion of enrollment in Longeveron's Phase 2a trial for Alzheimer's Disease -- -- Conference call scheduled for 8:30 a.m. ET today --

Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results

MIAMI, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced the completion of enrollment in its Phase 2a trial of Lomecel-BTM in patients with mild Alzheimer's Disease (AD).

Longeveron Announces Completion of Enrollment in Phase 2a Trial of Lomecel-B™ for the Treatment of Alzheimer's Disease

Live conference call on Monday, November 14 at 8:30 a.m. EST Live conference call on Monday, November 14 at 8:30 a.m. EST

Longeveron to Announce Third Quarter 2022 Financial Results on November 14, 2022

MIAMI, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today that Chris Min, M.D., Ph.D., Interim Chief Executive Officer, and Chief Medical Officer at Longeveron, will present at the upcoming Dawson James Small Cap Growth Conference taking place in Jupiter, Florida from October 11-12, 2022.

Longeveron to Present at the Annual Dawson James Small Cap Growth Conference

Executive brings more than 30 years of global biopharmaceutical operations and program management experience Executive brings more than 30 years of global biopharmaceutical operations and program management experience

Longeveron Names Jerome Bailey Vice President of Business Operations

MIAMI, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that Chris Min, M.D., Ph.D., Interim Chief Executive Officer, and Chief Medical Officer at Longeveron, will present at the upcoming H.C. Wainwright 24th Annual Global Investment Conference taking place in New York City from September 12-14, 2022.

Longeveron to Present at H.C. Wainwright 24th Annual Global Investment Conference

Source: shutterstock.com/Anastasia Zagoruyko Longeveron (NASDAQ: LGVN ) stock is on the move Wednesday after the FDA granted its fast-track designation for Lomecel-B. Lomecel-B is a allogeneic, bone marrow-derived medicinal signaling cell ( MSC ) product in development to treat Hypoplastic Left Heart Syndrome (HLHS) in infants.

Why Is Longeveron (LGVN) Stock on the Move Today?

New designation may expedite FDA review and potential approval to address this life-threatening heart condition affecting approximately 1,000 babies per year New designation may expedite FDA review and potential approval to address this life-threatening heart condition affecting approximately 1,000 babies per year

U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Longeveron's Lomecel-B™ Product for Treatment of Hypoplastic Left Heart Syndrome (HLHS) in Infants

Issued claims will protect use of a biomarker to assess response to Lomecel-B™ in patients with blood vessel dysfunction Issued claims will protect use of a biomarker to assess response to Lomecel-B™ in patients with blood vessel dysfunction

Longeveron Receives Intent to Grant Notice from the European Patent Office for Methods to Monitor Efficacy of Lomecel-B™ Cell Therapy Through Levels of Vascular Biomarker

Longeveron Inc. (NASDAQ:LGVN ) Q2 2022 Earnings Conference Call August 12, 2022 8:30 AM ET Company Participants Elsie Yau - Stern Investor Relations Chris Min - Interim Chief Executive Officer & Chief Medical Officer James Clavijo - Chief Financial Officer Joshua Hare - Co-Founder, Chief Science Officer & Chairman Conference Call Participants Michael Okunewitch - Maxim Group Operator Ladies and gentlemen, thank you for standing by. Welcome to the Longeveron 2022 Second Quarter Earnings Call.

Longeveron Inc. (LGVN) CEO Chris Min on Q2 2022 Results - Earnings Call Transcript

—Longeveron's Phase 2a trial of Lomecel-B for patients with mild Alzheimer's Disease proceeding on schedule, currently at 50% enrollment

Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Live conference call on Friday, August 12 at 8:30 a.m. EST Live conference call on Friday, August 12 at 8:30 a.m. EST

Longeveron to Announce Second Quarter 2022 Financial Results on August 12, 2022

MIAMI, July 07, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, today announced an abstract regarding the Lomecel-B Phase 2a trial in Alzheimer's Disease (AD) has been accepted for a poster presentation at the Alzheimer's Association International Conference (AAIC), being held July 31-August 4, 2022 in San Diego, California, as well as virtually.

Longeveron Announces Abstract Accepted for Presentation at the Alzheimer's Association International Conference (AAIC)

Longeveron Inc. (NASDAQ:LGVN ) Q1 2022 Earnings Conference Call May 13, 2022 8:30 AM ET Company Participants Elsie Yau - Stern Investor Relations, IR Geoff Green - CEO Chris Min - Chief Medical Officer James Clavijo - CFO Joshua Hare - Chief Science Officer Conference Call Participants Michael Okunewitch - Maxim Group Constantine Davides - EF Hutton Operator Hello everyone and welcome to the Longeveron Inc. 2022 First Quarter Earnings Call. My name is Juan and I will be coordinating your call today.

Longeveron Inc. (LGVN) CEO Geoff Green on Q1 2022 Results - Earnings Call Transcript

CRISPR Therapeutics

Enservco

Martin Midstream Partners

Summit Midstream Partners LP

Tema Electrification ETF

The same strategies for buying stocks during a bull market don't apply during a recession. Learn what you need to do going forward.

How to Buy Stocks in a Recession

Conference call scheduled for 8:30 a.m. ET today Conference call scheduled for 8:30 a.m. ET today

Longeveron Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results

-Geoff Green stepping down as CEO, effective June 1, 2022

Longeveron Announces CEO Transition

Live conference call at 8:30 a.m. EST Live conference call at 8:30 a.m. EST

Longeveron to Announce First Quarter 2022 Financial Results on May 13, 2022

Entera Bio Ltd

TRACON Pharmaceuticals

These three biotech companies have all had insiders buying shares recently. That's a good sign for the future of their treatments.

Follow the Insiders and Buy the Dip in These 3 Stocks

A phase 2a study using Lomecel-B for Alzheimer's Disease is currently enrolling patients; a prior phase 1 study established excellent safety profile with some efficacy. The global Alzheimer's Disease market could reach $25 billion by 2027.

Longeveron: Small-Cap Biotech Targeting Large Alzheimer's Market

April events to highlight Longeveron's commitment to developing cell therapeutics for chronic aging related diseases. April events to highlight Longeveron's commitment to developing cell therapeutics for chronic aging related diseases.

Longeveron to Present at Longevity Leaders World Congress; Latinos and Alzheimer's Symposium; International Frailty and Sarcopenia Research Conference

This third collaboration with the Miami VA shows Longeveron's commitment to improving the health of our nation's Veterans This third collaboration with the Miami VA shows Longeveron's commitment to improving the health of our nation's Veterans

Longeveron Enters into Cooperative Research and Development Agreement with the US Department of Veterans Affairs for its Phase 2 Alzheimer's Trial

Aterian

System1, Inc

Guardforce AI Co Ltd

Newegg Commerce

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

5 Short Squeeze Candidates To Watch: Aterian Tops The List, System1 Group And Longeveron Join Leaderboard

AstraZeneca

Biogen

Greenwich Lifesciences

GameStop

Roche Holding AG

Riot Blockchain

SPDR S&P Biotech ETF

Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now. The post Recession Fears are Creating a Golden Opportunity for Biotech Stocks appeared first on InvestorPlace.

News for Longeveron Stock (LGVN)